Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT05217407
Recruiting Observational

Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia

NCT05217407 · tracked via the Priya Life Science South Korea tracker
Sponsor
National Cancer Center, Japan
Phase
Observational
Started
2021-11-30
Last updated
2024-03-22

Condition(s) studied

Rare Malignant Neoplasm

Investigational drug(s) / intervention(s)

Genomic sequence

Genomic sequence: Genomic sequence

Study summary

This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing.

The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (Defined in protocol.) 2. Patients with Advanced stage cancer. Exclusion Criteria: 1\. Patients with complications of cognitive impairment.

Primary outcome measure(s)

Trial sites (18)

FacilityCityRegionStatus
National Cancer Center Hospital, Japan Chuo-ku Tokyo Recruiting
Hospital Sultan Ismail Johor Bahru Johor Recruiting
Hospital Pulau Pinang Pulau Pinang Pulau Pinang Recruiting
Sarawak General Hospital Kuching Sarawak Recruiting
Hospital Kuala Lumpur Kuala Lumpur Malaysia Recruiting
University Malaya Medical Center Kuala Lumpur Malaysia Recruiting
Institut Kanser negara Putrajaya Malaysia Recruiting
St. Luke's Medical Center Manila Philippines Recruiting
National Cancer Center Korea Seoul South Korea Recruiting
National Taiwan University Hospital Taipei Zhongzheng Recruiting
Taipei Veterans General Hospital Taipei Taiwan Recruiting
Mahidol University by Faculty of Medicine, Ramathibodi Hospita Bangkok Thailand Recruiting
Mahidol University by Faculty of Medicine, Siriraj Hospital Bangkok Thailand Recruiting
Maharaj Nakorn Chiang Mai Hospital Chiang Mai Thailand Not Yet Recruiting
Faculty of Medicine, Prince of Songkla University Hat Yai Thailand Recruiting
Khon Kaen University by Faculty of Medicine, Srinagarind Hospital Khon Kaen Thailand Recruiting
National Cancer Vietnam Hanoi Vietnam Recruiting
Ho Chi Minh City Oncology Hospital Ho Chi Minh City Vietnam Not Yet Recruiting

More National Cancer Center, Japan trials in South Korea

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05217407 on ClinicalTrials.gov ↗ ← All trials in South Korea